AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Cumberland Pharmaceuticals Inc.
Video analysis: CPIX
All videosNo video analysis for this stock yet. Request one from our team.
News: CPIX
Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown of
Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity
Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer metastasis, systemic sclerosis, and IPF.
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.87 and traded as high as $8.15. Cumberland Pharmaceuticals shares last traded at $7.96, with a volume of 79,334 shares traded. Analysts Set New Price Targets CPIX has
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Cumberland Pharmaceuticals NASDAQ: CPIX reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to Apotex Health.
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
$100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful closing of its Strategic Transaction with Apotex Health.
Possible Generic Drug Tariffs and 2 Microcaps
Generic drug tariffs could impact ELTP and CPIX.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.
